These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 25232731)

  • 1. Avian influenza A H7N9 virus induces severe pneumonia in mice without prior adaptation and responds to a combination of zanamivir and COX-2 inhibitor.
    Li C; Li C; Zhang AJ; To KK; Lee AC; Zhu H; Wu HW; Chan JF; Chen H; Hung IF; Li L; Yuen KY
    PLoS One; 2014; 9(9):e107966. PubMed ID: 25232731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The neuraminidase inhibitor oseltamivir is effective against A/Anhui/1/2013 (H7N9) influenza virus in a mouse model of acute respiratory distress syndrome.
    Baranovich T; Burnham AJ; Marathe BM; Armstrong J; Guan Y; Shu Y; Peiris JM; Webby RJ; Webster RG; Govorkova EA
    J Infect Dis; 2014 May; 209(9):1343-53. PubMed ID: 24133191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human H7N9 virus induces a more pronounced pro-inflammatory cytokine but an attenuated interferon response in human bronchial epithelial cells when compared with an epidemiologically-linked chicken H7N9 virus.
    To KK; Lau CC; Woo PC; Lau SK; Chan JF; Chan KH; Zhang AJ; Chen H; Yuen KY
    Virol J; 2016 Mar; 13():42. PubMed ID: 26975414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A(H7N9) virus results in early induction of proinflammatory cytokine responses in both human lung epithelial and endothelial cells and shows increased human adaptation compared with avian H5N1 virus.
    Zeng H; Belser JA; Goldsmith CS; Gustin KM; Veguilla V; Katz JM; Tumpey TM
    J Virol; 2015 Apr; 89(8):4655-67. PubMed ID: 25673714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in the pathogenicity and inflammatory responses induced by avian influenza A/H7N9 virus infection in BALB/c and C57BL/6 mouse models.
    Zhao G; Liu C; Kou Z; Gao T; Pan T; Wu X; Yu H; Guo Y; Zeng Y; Du L; Jiang S; Sun S; Zhou Y
    PLoS One; 2014; 9(3):e92987. PubMed ID: 24676272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Laninamivir octanoate and artificial surfactant combination therapy significantly increases survival of mice infected with lethal influenza H1N1 Virus.
    Fukushi M; Yamashita M; Miyoshi-Akiyama T; Kubo S; Yamamoto K; Kudo K
    PLoS One; 2012; 7(8):e42419. PubMed ID: 22879974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Protective Effects of the A/ZJU01/ PR8/2013 Split H7N9 Avian Influenza Vaccine Against Highly Pathogenic H7N9 in BALB/c Mice.
    Wu XX; Deng XL; Yu DS; Yao W; Ou HL; Weng TH; Hu CY; Hu FY; Wu NP; Yao H; Zhang FC; Li LJ
    Cell Physiol Biochem; 2018; 46(2):633-643. PubMed ID: 29617693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of zanamivir against avian influenza A viruses that possess genes encoding H5N1 internal proteins and are pathogenic in mammals.
    Leneva IA; Goloubeva O; Fenton RJ; Tisdale M; Webster RG
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1216-24. PubMed ID: 11257037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sialic acid-binding protein Sp2CBMTD protects mice against lethal challenge with emerging influenza A (H7N9) virus.
    Govorkova EA; Baranovich T; Marathe BM; Yang L; Taylor MA; Webster RG; Taylor GL; Connaris H
    Antimicrob Agents Chemother; 2015 Mar; 59(3):1495-504. PubMed ID: 25534734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural analysis of the novel influenza A (H7N9) viral Neuraminidase interactions with current approved neuraminidase inhibitors Oseltamivir, Zanamivir, and Peramivir in the presence of mutation R289K.
    Tran-To Su C; Ouyang X; Zheng J; Kwoh CK
    BMC Bioinformatics; 2013; 14 Suppl 16(Suppl 16):S7. PubMed ID: 24564719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combinations of oseltamivir and fibrates prolong the mean survival time of mice infected with the lethal H7N9 influenza virus.
    Xu L; Bao L; Li F; Gu S; Lv Q; Yuan J; Xu Y; Zhu H; Deng W; Li Y; Yao Y; Yu P; Gao Z; Qin C
    J Gen Virol; 2015 Jan; 96(Pt 1):46-51. PubMed ID: 25274854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility.
    Hai R; Schmolke M; Leyva-Grado VH; Thangavel RR; Margine I; Jaffe EL; Krammer F; Solórzano A; García-Sastre A; Palese P; Bouvier NM
    Nat Commun; 2013; 4():2854. PubMed ID: 24326875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low replicative fitness of neuraminidase inhibitor-resistant H7N9 avian influenza a virus with R292K substitution in neuraminidase in cynomolgus macaques compared with I222T substitution.
    Suzuki S; Shichinohe S; Itoh Y; Nakayama M; Ishigaki H; Mori Y; Ogata-Nakahara A; Nguyen CT; Okamatsu M; Sakoda Y; Kida H; Ogasawara K
    Antiviral Res; 2020 Jun; 178():104790. PubMed ID: 32272175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human H7N9 and H5N1 influenza viruses differ in induction of cytokines and tissue tropism.
    Meliopoulos VA; Karlsson EA; Kercher L; Cline T; Freiden P; Duan S; Vogel P; Webby RJ; Guan Y; Peiris M; Thomas PG; Schultz-Cherry S
    J Virol; 2014 Nov; 88(22):12982-91. PubMed ID: 25210188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of clarithromycin against H5N1 and H7N9 avian influenza a virus infection in cynomolgus monkeys.
    Arikata M; Itoh Y; Shichinohe S; Nakayama M; Ishigaki H; Kinoshita T; Le MQ; Kawaoka Y; Ogasawara K; Shimizu T
    Antiviral Res; 2019 Nov; 171():104591. PubMed ID: 31421167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of H7N9 influenza A viruses isolated from humans.
    Watanabe T; Kiso M; Fukuyama S; Nakajima N; Imai M; Yamada S; Murakami S; Yamayoshi S; Iwatsuki-Horimoto K; Sakoda Y; Takashita E; McBride R; Noda T; Hatta M; Imai H; Zhao D; Kishida N; Shirakura M; de Vries RP; Shichinohe S; Okamatsu M; Tamura T; Tomita Y; Fujimoto N; Goto K; Katsura H; Kawakami E; Ishikawa I; Watanabe S; Ito M; Sakai-Tagawa Y; Sugita Y; Uraki R; Yamaji R; Eisfeld AJ; Zhong G; Fan S; Ping J; Maher EA; Hanson A; Uchida Y; Saito T; Ozawa M; Neumann G; Kida H; Odagiri T; Paulson JC; Hasegawa H; Tashiro M; Kawaoka Y
    Nature; 2013 Sep; 501(7468):551-5. PubMed ID: 23842494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of substitutions in the neuraminidase of A(H7N9) influenza viruses selected following serial passage in the presence of different neuraminidase inhibitors.
    Farrukee R; Butler J; Reading PC; Hurt AC
    Antiviral Res; 2019 Aug; 168():68-75. PubMed ID: 31132385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of laninamivir octanoate in mice with advanced inflammation stage caused by infection of highly lethal influenza virus.
    Tomozawa T; Hoshino K; Yamashita M; Kubo S
    J Infect Chemother; 2019 Aug; 25(8):584-588. PubMed ID: 30935767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The novel human influenza A(H7N9) virus is naturally adapted to efficient growth in human lung tissue.
    Knepper J; Schierhorn KL; Becher A; Budt M; Tönnies M; Bauer TT; Schneider P; Neudecker J; Rückert JC; Gruber AD; Suttorp N; Schweiger B; Hippenstiel S; Hocke AC; Wolff T
    mBio; 2013 Oct; 4(5):e00601-13. PubMed ID: 24105764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. H7N9 and other pathogenic avian influenza viruses elicit a three-pronged transcriptomic signature that is reminiscent of 1918 influenza virus and is associated with lethal outcome in mice.
    Morrison J; Josset L; Tchitchek N; Chang J; Belser JA; Swayne DE; Pantin-Jackwood MJ; Tumpey TM; Katze MG
    J Virol; 2014 Sep; 88(18):10556-68. PubMed ID: 24991006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.